Cargando…

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients

Detalles Bibliográficos
Autores principales:	Harky, Amer, Chor, Cheryl Yan Ting, Nixon, Henry, Jeilani, Milad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	COVID-19 and the Renin-Angiotensin-Aldosterone System
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797594/ https://www.ncbi.nlm.nih.gov/pubmed/33412991 http://dx.doi.org/10.1177/1470320320987118

Ejemplares similares

Could angiotensin-converting enzyme 1 I/D polymorphism be a modificator of COVID-19 response in different populations, diseases, and/or conditions?
por: Dević Pavlić, Sanja, et al.
Publicado: (2020)

Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads
por: Hoevenaar, Martijn, et al.
Publicado: (2020)

Angiotensin II, III, and IV may be important in the progression of COVID-19
por: Cure, Erkan, et al.
Publicado: (2020)

The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?
por: Sever, Peter, et al.
Publicado: (2020)

In vitro analysis of the renin–angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus
por: Turk, Can, et al.
Publicado: (2020)

Cardiovascular disease, heart failure and COVID-19
por: Faconti, Luca, et al.
Publicado: (2020)

Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension
por: Cure, Erkan, et al.
Publicado: (2020)

Countermeasure and therapeutic: A(1–7) to treat acute respiratory distress syndrome due to COVID-19 infection
por: Soto, Maira, et al.
Publicado: (2020)

COVID-19 and the pulmonary vascular injury
por: Dai, Hai-Long, et al.
Publicado: (2020)

COVID-19 and hypertension
por: Kulkarni, Spoorthy, et al.
Publicado: (2020)

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression
por: Pranata, Raymond, et al.
Publicado: (2020)

COVID-19: The race for a vaccine
por: Lockey, Emily
Publicado: (2020)

Effects of ACEI and ARB on COVID-19 patients: A meta-analysis
por: Xue, Yang, et al.
Publicado: (2020)

Angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin‐converting enzyme 2 in patients with cardiovascular disease
por: Lebek, Simon, et al.
Publicado: (2020)

Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
por: Komiyama, Maki, et al.
Publicado: (2020)

Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust
por: Bean, Daniel M., et al.
Publicado: (2020)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
por: Kim, Ju Hwan, et al.
Publicado: (2020)

WCN23-0291 USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEIs) AND ANGIOTENSIN-RECEPTOR BLOCKERS (ARBs) AND INCIDENCE OF PNEUMONIA OR INFLUENZA OR COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Qin, X., et al.
Publicado: (2023)

The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study
por: Butler-Laporte, Guillaume, et al.
Publicado: (2020)

Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea
por: Jung, Mi‐Hyang, et al.
Publicado: (2021)

Angiotensin converting enzyme and sodium glucose cotransporter inhibitors alleviate inflammatory effects of SARS-CoV-2 in cardiomyocytes
por: Wong, Chun-Ka, et al.
Publicado: (2022)

COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
por: Genet, Bastien, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Serum aldosterone effect on left ventricular structure and diastolic function in essential hypertension
por: Al‐Hashedi, Ekhlas Mahmoud, et al.
Publicado: (2022)

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
por: Simko, Fedor, et al.
Publicado: (2021)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Angiotensin-converting enzyme 2, the SARS-CoV-2 cellular receptor, is widely expressed in human myometrium and uterine leiomyoma
por: Racilan, Alexon M, et al.
Publicado: (2021)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease – Demystifying controversies
por: Muneer, Kader, et al.
Publicado: (2017)

The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
por: Coto, Eliecer, et al.
Publicado: (2021)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure
por: Muslim, Shahnawaz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4f2nl0s5s3n9c47a9cfbjkmv37